Chiropractors in Prospect, CT Accepting Medicare

3 Chiropractors found. Showing 1 - 3

Nicholas A Forte Jr., DC Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 16 Waterbury Rd, Prospect, CT 06712 Phone: 203-758-3391    Fax: 203-758-0358

Dr. Thomas M Patavino, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 60 Waterbury Rd, Suite C, Prospect, CT 06712 Phone: 203-758-7250    Fax: 203-758-7266

Thoracic Park Alternative Health Chiropractor Medicare: Medicare Enrolled Practice Location: 60 Waterbury Rd, Suite C, Prospect, CT 06712 Phone: 203-758-7250

News Archive

FDA issues import alert on drug products manufactured at Ranbaxy's facility in Mohali, India

The U.S. Food and Drug Administration today issued an import alert under which U.S. officials may detain at the U.S. border drug products manufactured at Ranbaxy Laboratories, Ltd.'s facility in Mohali, India.

Sugary drinks may be addictive and are harmful to health, study suggests

Just as we might have guessed, those tasty, sugar-sweetened beverages that increase risk of diabetes and other chronic diseases may actually be addictive.

Review of addiction to prescription painkillers

Chemical dependency and recovery in patients and physicians are closely examined in a series of articles and editorials in the July 2009 issue of Mayo Clinic Proceedings. The subject is especially timely. As the immense challenges, including potential tragedies, of prescription chemical addiction and abuse are being discussed, these articles offer crucial overview, direction and optimism.

CREST study data published in The New England Journal of Medicine

Data from the CREST (Carotid Revascularization Endarterectomy vs. Stenting Trial) study were published today in The New England Journal of Medicine. In this trial, stenting and surgery had similar initial safety and longer-term outcomes for symptomatic and asymptomatic men and women. Adverse event rates of death, stroke and heart attack were also similar for both therapies.

Preliminary results from Boehringer Ingelheim's volasertib Phase II study on AML

Boehringer Ingelheim Pharmaceuticals, Inc. today reported preliminary results from the randomized Phase II part of a Phase I/II study involving the company's investigational compound volasertib in newly diagnosed patients with acute myeloid leukemia (AML) considered ineligible for intensive remission induction therapy.

Read more Medical News

› Verified 9 days ago